Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.

@article{Ha2012RescueTF,
  title={Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.},
  author={Minghao Ha and Guotong Zhang and Shu Diao and Mingfang Lin and Jianqiu Wu and Liping Sun and Huiyuan She and Lihui Shen and Chunhong Huang and Wenjuan Shen and Zhongming Huang},
  journal={Internal medicine},
  year={2012},
  volume={51 12},
  pages={1509-15}
}
OBJECTIVE We aimed to compare the cumulative efficacy and resistance of ADV monotherapy, ADV add-on LAM (ADV + LAM), ADV and ETV (ADV + ETV) combination therapy in LAM-resistant patients. METHODS Ninety-one adult CHB patients with LAM-resistance mutations (YMDD) were identified. Of these 91, 29 patients were treated with ADV monotherapy, 30 were treated with ADV + LAM and 32 were treated with ADV + ETV combination therapy, for at least 24 months. RESULTS The mean serum HBV-DNA decreases… CONTINUE READING

From This Paper

Topics from this paper.
10 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…